Tag Archives: immunotherapy

FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma

PRINCETON, N.J.–(BUSINESS WIRE) October 2, 2020 — Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 360 mg every three weeks plus Yervoy (ipilimumab) 1 mg/kg every six weeks (injections for intravenous use) was approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment of adult patients with unresectable malignant pleural… Read More »

Medical News Today: Cancer: Using copper to boost immunotherapy

An interdisciplinary group of scientists has successfully destroyed tumor cells in mice by using nano-sized copper compounds alongside immunotherapy. Importantly, the tumors did not return after the treatment ceased. According to the World Health Organization, cancer is the second leading cause of death worldwide — in 2018, it was responsible for approximately 9.6 million deaths.… Read More »

Cancer immunotherapy drug ‘less toxic and prolongs life’

An immunotherapy drug that could save some cancer patients from the ordeal of extreme chemotherapy may also help them live longer, researchers say. In a trial, pembrolizumab kept head and neck cancers at bay for an average of two years – five times longer than under chemotherapy. The patients also suffered far fewer side-effects. Cases… Read More »